Veeda Oncology, the subsidiary of one of the leading Global CRO’s in India, Veeda Clinical Research, has completed the acquisition of Biologie et Industrie (B&I), an Oncology CRO founded in 1984, based in Paris, France. The acquisition of B & I, with over 20 years of oncology CRO experience, significantly compliments Veeda Oncology’s capability within mainland Europe. Announcing the acquisition, Mr. Binoy Gardi, Co-Managing Director of the Veeda Group, said “the acquisition of B&I is one significant pillar that we are adding to our global oncology presence within the oncology CRO marketplace”. Mr. Gardi added that “the clients of B&I will now be able to enjoy the strong global oncology patient accrual ability that currently exists within Veeda Oncology as well as the other full service capabilities that Veeda Oncology provides to their clients”. Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure. Veeda Oncology feels that the acquisition of B&I truly strengthens Veeda Oncology’s capabilities  Dr. R

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.